Recipient CYP2D6*4 Poor Metabolizer Status Associates with Early Fibrosis Development after Liver Transplantation

被引：0
|
作者：
Zimmermann, Tim [1 ]
Hoppe-Lotichius, Maria
Lautem, Anja
Schuchmann, Marcus [1 ]
Otto, Gerd
机构：
[1] Johannes Gutenberg Univ Mainz, Dept Med 1, D-6500 Mainz, Germany
来源：
LIVER TRANSPLANTATION | 2011年 / 17卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S234 / S234
页数：1
相关论文
共 50 条
  • [1] RECIPIENT CYP2D6*4 POOR METABOLIZER STATUS ASSOCIATES WITH EARLY FIBROSIS DEVELOPMENT AFTER LIVER TRANSPLANTATION
    Zimmermann, T.
    Hoppe-Lotichius, M.
    Koerner, A.
    Lautem, A.
    Heise, M.
    Galle, P. R.
    Otto, G.
    Schuchmann, M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S237 - S238
  • [2] The recipient CYP2D6 allele 4-associated poor metabolizer status correlates with an early fibrosis development after liver transplantation
    Zimmermann, Tim
    Hoppe-Lotichius, Maria
    Koerner, Andreas
    Lautem, Anja
    Heise, Michael
    Foltys, Daniel
    Weiler, Nina
    Biesterfeld, Stefan
    Schmidtmann, Irene
    Galle, Peter R.
    Otto, Gerd
    Schuchmann, Marcus
    TRANSPLANT INTERNATIONAL, 2011, 24 (11) : 1059 - 1067
  • [3] ROLE OF THE CYP2D6 POOR METABOLIZER STATUS ON THE FIBROSIS PROGRESSION AFTER LIVER TRANSPLANTATION
    Zimmermann, T.
    Hoppe-Lotichius, M.
    Koerner, A.
    Lautem, A.
    Galle, P. R.
    Schuchmann, M.
    Otto, G.
    TRANSPLANT INTERNATIONAL, 2010, 23 : 3 - 3
  • [4] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation:: a study of mutations CYP2D6*3 and CYP2D6*4
    Monek, O
    Paintaud, G
    Bechtel, Y
    Miguet, JP
    Mantion, G
    Bechtel, PR
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) : 47 - 52
  • [5] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4
    O. Monek
    G. Paintaud
    Y. Bechtel
    J. P. Miguet
    G. Mantion
    P. R. Bechtel
    European Journal of Clinical Pharmacology, 1998, 54 : 47 - 52
  • [6] CYP2D6*36 gene arrangements within the CYP2D6 locus:: Association of CYP2D6*36 with poor metabolizer status
    Gaedigk, A
    Bradford, LD
    Alander, SW
    Leeder, JS
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 563 - 569
  • [7] CYP2D6 metabolizer status and postoperative analgesia with tramadol
    Wilder-Smith, CH
    Wilkins, J
    ANESTHESIOLOGY, 1999, 91 (3A) : U416 - U416
  • [8] CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
    Almoguera, Berta
    Riveiro-Alvarez, Rosa
    Lopez-Castroman, Jorge
    Dorado, Pedro
    Vaquero-Lorenzo, Concepcion
    Fernandez-Piqueras, Jose
    LLerena, Adrian
    Abad-Santos, Francisco
    Baca-Garcia, Enrique
    Dal-Re, Rafael
    Ayuso, Carmen
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (11): : 627 - 630
  • [9] Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer
    Susce, Margaret T.
    Murray-Carmichael, Elaina
    de Leon, Jose
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (07): : 1356 - 1358
  • [10] Unique case of serotonin toxicity in a poor CYP2D6 metabolizer
    Feininger, E. Sterling
    Dulaney, Anna
    Sanders, Taylor
    Pikus, Angela
    Kopec, Kathryn
    CLINICAL TOXICOLOGY, 2023, 61 : 71 - 71
12345